Skip to main content

Nyxoah SA (NYXH)

NASDAQ: NYXH · Delayed Price · USD
29.75
-0.25 (-0.83%)
Pre-market:Sep 20, 2021 7:00 AM EDT
30.00
0.00 (0.00%)
At close: Jul 1, 12:00 AM
Market Cap746.03M
Revenue (ttm)309,000
Net Income (ttm)-18.91M
Shares Out24.87M
EPS (ttm)-0.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume204
Open30.69
Previous Close30.00
Day's Range30.67 - 32.95
52-Week Range0.00 - 32.95
Betan/a
Analystsn/a
Price Target41.49 (+38.3%)
Est. Earnings DateNov 30, 2021

About NYXH

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA. Our lead solution is the Genio system, a CE-Marked, patient-centric, minimally invasive, next generation hypoglossal neurostimulation therapy for the treatment of moderate to severe OSA. Our innovative technology platform is a first-of-its-kind bilateral hypoglossal nerve stimulation device designed to treat OSA, by maintaining an open airway for a restful night’s sleep. We started generatin...

IndustryMedical Instruments & Supplies
IPO DateJul 2, 2021
CEOOlivier Taelman
Employees71
Stock ExchangeNASDAQ
Ticker SymbolNYXH
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

Nyxoah's Sleep Apnea Device Receives FDA Breakthrough Tag

The FDA has granted Breakthrough Device Designation to Nyxoah SA (NASDAQ: NYXH) Genio bilateral hypoglossal nerve stimulation system. The system treats adult patients with moderate to severe Obstructive...

5 days ago - Benzinga

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Nyxoah Announc es Participation in the Cantor 2021 Virtual Global Healthcare Conference

6 days ago - GlobeNewsWire

Publication relating to transparency notifications

PRESS RELEASE

2 weeks ago - GlobeNewsWire

Nyxoah Issues First Half 2021 Financial Results

REGULATED INFORMATION

2 weeks ago - GlobeNewsWire

Should You Buy Nyxoah (NYXH) Ahead of Earnings?

Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 weeks ago - Zacks Investment Research

Nyxoah Appoints Rita Johnson-Mills to its Board of Directors

Nyxoah Appoints Rita Johnson-Mills to its Board of Directors

3 weeks ago - GlobeNewsWire

Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021

Mont-Saint-Guibert, Belgium. - August 11, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the developmen...

1 month ago - GlobeNewsWire

Publication relating to a transparency notification

PRESS RELEASE REGULATED INFO R MATION

2 months ago - GlobeNewsWire

Nyxoah Announces Pricing of Nasdaq Public Offering

Mont-Saint-Guibert, Belgium – July 2, 2021, 2:40pm CET / 8:40am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and c...

2 months ago - GlobeNewsWire

Nyxoah Announces Launch of Proposed Public Offering in the United States

REGULATED INFORMATION - INSIDE INFORMATION Nyxoah Announces Launch of Proposed Public Offering in the United States...

2 months ago - GlobeNewswire

Nyxoah IPO Registration Document (S-1)

Nyxoah SA has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC